Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.

Overview of attention for article published in Journal of Clinical Oncology, June 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 1 patent

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 1 X post from an account with 1,407 followers.

@VincentRK This is the dara v. observation study in SMM that was mentioned by @VincentRK https://t.co/upyjCBCxP9

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.